Regeneron Pharmaceuticals (REGN) Net Income towards Common Stockholders (2009 - 2026)

Regeneron Pharmaceuticals' Net Income towards Common Stockholders history runs 18 years deep, the most recent figure standing at $727.2 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 10.08% year-over-year to $727.2 million in Q1 2026; TTM through Mar 2026 was $4.4 billion, a 1.69% decrease from a year earlier, with the FY2025 full-year figure at $4.5 billion, up 2.09% from the prior year.
• Net Income towards Common Stockholders declined to $727.2 million in Q1 2026 per REGN's latest filing, from $844.6 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $1.5 billion in Q3 2025 and bottomed at $722.0 million in Q1 2024.
• The 5-year median for Net Income towards Common Stockholders is $973.5 million (2022), against an average of $1.1 billion.
• Across the five-year window, Net Income towards Common Stockholders slumped 72.5% in 2022 and surged 47.9% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $1.2 billion in 2022, then retreated by 3.13% to $1.2 billion in 2023, then decreased by 20.86% to $917.7 million in 2024, then dropped by 7.97% to $844.6 million in 2025, then retreated by 13.9% to $727.2 million in 2026.
• Per Business Quant, the three latest REGN Net Income towards Common Stockholders figures stand at $727.2 million (Q1 2026), $844.6 million (Q4 2025), and $1.5 billion (Q3 2025).